[an error occurred while processing this directive] | [an error occurred while processing this directive]
Final report of a prospective randomized study on thoracic radiotherapy target volumes for limited-stage small cell lung cancer
Hu Xiao, Bao Yong, Xu Yujin, Zhang Li, Wang Jin, Ma Honglian, Jin Ying, Xu Xiaoling, Song Zhengbo, Peng Fang, Tang Huarong, Fang Min, Kong Yue, Chen Mengyuan, Dong Baiqiang, Yu Xinmin, Lu Hongyang, Zhang Yiping, Fan Yun, Chen Ming
Department of Radiation Oncology (Hu X,Xu YJ,Wang GJ,Ma HL,Tang HR,Fang M,Kong Y,Chen MY,Dong BQ,Chen M),Department of Medical Oncology (Jin Y,Xu XL,Song ZB,Yu XM,Lu HY,Zhang YP,Fan Y),Zhejiang Cancer Hospital,Zhejiang Provincial Key Laboratory of Radiation Oncology,Hangzhou 310022,China; Department of Radiation Oncology,First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510060,China (Bao Y,Peng F); Department of Medical Oncology,Cancer Center of Sun Yat-sen University,Guangzhou 510060,China (Zhang L)
AbstractObjective In view of the controversy over radiotherapy target volume for patients with limited-stage small cell lung cancer (SCLC),a prospective randomized controlled trial was conducted to compare the impact of different radiotherapy target volumes on prognosis. Methods After 2 cycles of EP chemotherapy,patients without progressive disease were randomly assigned to receive thoracic radiotherapy (TRT) to either the post-or pre-chemotherapy primary tumour extent as study arm or control. Involved field radiotherapy (IFRT) to the entire metastatic lymph node regions was applied for both arms. TRT consisted of 45 Gy/30Fx/19 d administered concurrently with cycle 3 chemotherapy. Prophylactic cranial irradiation was administered to patients achieved complete or partial remission. Kaplan-Meier method was used for survival analysis. Results Between June 2002 and December 2017,159 and 150 patients were randomly assigned to study arm and control respectively. The 1-,2-,and 5-year local/regional control rates were 79.4%,61.5% and 60.1% respectively in the study arm versus 79.8%,66.5%,and 57.3% in the control arm (P=0.73).The median OS time was 22.1 months in the study arm (95%CI,18.2-26.0 months) and 26.9 months (95%CI,23.5-30.3 months) in the control arm,the 1-,3-,5-,and 7-year OS rates were 81.1%,31.6%,23.9% and 22.2% respectively in the study arm versus 85.3%,36.6%,26.1% and 20.0% in the control arm (P=0.51).Grade 2-3 acute esophagitis was developed in 32.9% and 43.2% of patients respectively in study arm and control arm (P=0.01),while grade 2-3 pulmonary fibrosis was observed in 2.0% and 10.9% of patients (P=0.01) respectively. Conclusions For patients with limited-stage SCLC who received induction chemotherapy,thoracic radiotherapy can be limited to post-chemotherapy tumour extent and IFRT can be routinely applied.
Fund:National Natural Science Foundation of China (81402540,81401911,81672972);The national health and family planning commission scientific research funds-Zhejiang province major science and technology project on medicine (WKJ-ZJ-1701)
Hu Xiao,Bao Yong,Xu Yujin et al. Final report of a prospective randomized study on thoracic radiotherapy target volumes for limited-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1046-1050.
Hu Xiao,Bao Yong,Xu Yujin et al. Final report of a prospective randomized study on thoracic radiotherapy target volumes for limited-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1046-1050.
[1] van Meerbeeck JP,Fennell DA,De Ruysscher DK.Small-cell lung cancer[J].Lancet,2011,378(9804):1741–1755.DOI:10.1016/S0140-6736(11)60165-7. [2] Turrisi AT,Kim K,Blum R,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].N Engl J Med,1999,340(4):265-271.DOI:10.1056/NEJM199901283400403. [3] Takada M,Fukuoka M,Kawahara M,et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer:results of the Japan Clinical Oncology Group Study 9104[J].J Clin Oncol,2002,20(14):3054-3060.DOI:10.1200/JCO.2002.12.071. [4] Videtic GM,Belderbos JS,Spring Kong FM,et al. Report from the International Atomic Energy Agency (IAEA) consultants′ meeting on elective nodal irradiation in lung cancer:small-cell lung cancer (SCLC)[J].Int J Radiat Oncol Biol Phys,2008,72(2):327–334.DOI:10.1016/j.ijrobp.2008.03.075. [5] Cox JD,Stetz J,Pajak TF.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J].Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346.DOI:10.1016/0360-3016(95)00060-C. [6] De Ruysscher D,Bremer RH,Koppe F,et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer:A phase Ⅱ trial[J].Radiother Onco,.2006,80(3):307–312.DOI:10.1016/j.radonc.2006.07.029. [7] van Loon J,De Ruysscher D,Wanders R,et al. Selective nodal irradiation on basis of (18) FDG-PET scans in limited-disease small-cell lung cancer:a prospective study[J].Int J Radiat Oncol Biol Phys,2010,77(2):329-336.DOI:10.1016/j.ijrobp.2009.04.075. [8] Hu X,Bao Y,Zhang L,et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer:interim analysis of a prospective randomized noninferiority trial[J].Cancer,2012,118(1):278-287.DOI:10.1002/cncr.26119. [9] Xia B,Chen GY,Cai XW,et al. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer?[J].Radiother Oncol,2012;102(2):258-262.DOI:10.1016/j.radonc.2011.10.003. [10] Colaco R,Sheikh H,Lorigan P,et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer—evidence from a phase Ⅱ trial[J].Lung Cancer,2012,76(1):72-77.DOI:10.1016/j.lungcan.2011.09.015. [11] 胡晓,包勇,何智纯,等.局限期小细胞肺癌累及野放疗淋巴结区域受照剂量与失败关系的研究[J].中华放射医学与防护杂志,2015,35(8):580-583.DOI:10.3760/cma.j.issn.0254-5098.2015.08.005. Hu X,Bao Y,He ZC,et al. Correlations between the irradiated dose to lymph node regions and lymph node recurrence when involved field radiotherapy used for limited-stage small cell lung cancer[J].Chin J Radiol Med Prot,2015,35(8):580-583.DOI:10.3760/cma.j.issn.0254-5098.2015.08.005. [12] Withers HR,Peters LJ,Taylor JM.Dose-response relationship for radiation therapy of subclinical disease[J].Int J Radiat Oncol Biol Phys,1995,31(2):353-359.DOI:10.1016/0360-3016(94)00354-N. [13] De Ruysscher D,Pijls-Johannesma M,Bentzen SM,et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer[J].J Clin Oncol,2006,24(7):1057-1063.DOI:10.1200/JCO.2005.02.9793. [14] De Ruysscher D,Lueza B,Le Péchoux C,et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J].Ann Oncol,2016,27(10):1818-1828.DOI:10.1093/annonc/mdw263. [15] Faivre-Finn C,Snee M,Ashcroft L,et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label,phase 3,randomised,superiority trial[J].Lancet Oncol,2017,18(8):1116-1125.DOI:10.1016/S1470-2045(17)30318-2. [16] Sun JM,Ahn YC,Choi EK,et al. Phase Ⅲ trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer[J].Ann Oncol,2013,24(8):2088–2092.DOI:10.1093/annonc/mdt140. [17] Wang Y,Bao Y,Zhang L,et al. Assessment of respiration-induced motion and its impact on treatment outcome for lung cancer[J].Biomed Res Int,2013,2013:872739.DOI:10.1155/2013/872739.
2018, Vol. 27 
